A $6B Opportunity
Ironwood's Linzess Beats PDUFA Date to Approval in IBS
By Marie Powers
Friday, August 31, 2012
Ironwood Pharmaceuticals Inc. crossed the commercial threshold Thursday morning, gaining FDA approval of irritable bowel syndrome (IBS) drug linaclotide more than a week ahead of the drug's Sept. 9 PDUFA date.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.